Mind Medicine (MindMed) (MNMD) Stock Price & Analysis

MNMD$20.69+0.09 +0.44%
Biotechnology
Compare
Market cap$1.56BEnterprise value$1.32BRevenue (TTM)$0Market position—

Score

38
Bearish
Value
48
Quality
51
Growth
16

AI Analysis

Snapshot

Mind Medicine (MindMed) doesn’t screen as a clean setup today — Stocklytics 38/100 leaves more to prove. In Biotechnology, that score mix is usable but not one-dimensional.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

48
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

16
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

51
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Mind Medicine (MindMed) Inc. (MNMD) last printed $20.69. Equity value is $1.56B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00

About

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering new treatments for various brain health conditions, encompassing psychiatric disorders, addiction, pain, and neurological ailments. Among its key pipeline assets is MM-120, currently undergoing Phase 2 clinical trials. This candidate is being investigated for its potential in addressing generalized anxiety disorder, attention deficit hyperactivity disorder (ADHD), and chronic pain. Furthermore, MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, has successfully completed Phase 1 studies for managing opioid withdrawal. The company's portfolio also includes MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine, aimed at treating the core symptoms associated with autism spectrum disorder. Its corporate headquarters are situated in Vancouver, Canada.

Mind Medicine (MindMed) (MNMD) Stock Price & Analysis

MNMD price $20.69 +0.09 +0.44%

Ticker
MNMD
Price
$20.69
Change
+0.09 +0.44%
Market cap
$1.56B
Forward P/E
22.09
Dividend yield
0.00%
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
38
Value
48
Quality
51
Growth
16

Stocklytics score rationale: value 48, quality 51, growth 16.

Insights · Forecast · Financials · Learn

Stocklytics home · Screener